Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics

Core Viewpoint - Analysts expect Medtronic to report quarterly earnings of $1.23 per share, indicating no change from the previous year, with revenues projected at $8.37 billion, reflecting a 5.7% increase year-over-year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1][2] Revenue Projections - Analysts predict 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' at $728.31 million, a year-over-year increase of 2.2% [4] - 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' is expected to reach $631.16 million, reflecting a 2.5% increase [4] - 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' is forecasted at $1.20 billion, indicating a 5% increase [5] - 'Net Sales- U.S. Revenue' is estimated at $4.26 billion, suggesting a 4.3% year-over-year change [6] - 'Net Sales- ROW- Cardiovascular' is projected to reach $1.71 billion, reflecting a 6.6% increase [8] Specific Segment Insights - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is expected to be $332.01 million, indicating a 6.4% increase [7] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is estimated at $326.25 million, reflecting a 3.9% increase [7] - 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' is projected at $960.12 million, indicating a 4.9% increase [8] Market Performance - Over the past month, Medtronic shares have recorded returns of 3.5%, aligning with the Zacks S&P 500 composite's performance [9]